Medicare wellness visits causing confusion

When the Affordable Care Act first went into effect, one of the perceived benefits for physicians was the three new billing codes that cover various “wellness visits” for Medicare Part B patients. But so far, the perk is failing to live up to expectations.

The visits in question include a “Welcome to Medicare” preventive visit for new patients and yearly wellness visits for patients who have been on Part B for more than 12 months. In theory, these are a huge benefit to both physicians and patients, because the physician gets to slow down, set a specific amount of time aside to review the patient’s medical history and provide personalized health advice. The entire visit is then billed to Medicare, with no co-pay.

As recently reported by MedPage Today, however, primary care physicians have been slow to submit codes for wellness visits, with just 12 percent of eligible Part B beneficiaries receiving these services.

One of the primary problems, as MedPage Today’s analysis points out, is that certain topics can’t be discussed or the appointment can’t technically be billed as a wellness visit. Patients in a doctor’s office ask about various issues they have been having, but the physician is put in the awkward position of saying, “we can’t talk about that at this time” or, “come back again and we can talk about that.”

Physicians don’t like saying this, patients don’t like being told this, and it often leads to something else being billed to Medicare altogether, or, at the very least, upset patients who may share the negative story of their visit with others

Another common problem physicians are encountering with wellness visits is that patients expect a full physical. Again, this often leads to confusion and unhappy patients.

Medicare’s website includes detailed information about these wellness visits. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.